Clinical trials: Time Management
- Condition Time Management
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Respiratory Tract Infections
Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of PF-04287881 after a single oral dose in healthy adult volunteers.
- Trial name
- NCT00793000
- Testing
- PF-04287881
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Hyperemia
Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.
To characterize the plasma pharmacokinetics and safety profile of brimonidine following a single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution 0.025% for 7 days in healthy, adult subjects.
- Trial name
- NCT02039765
- Testing
- Brimonidine tartrate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Healthy
A Study Comparing User Experience of Different Delivery Devices for Glucagon
The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies.
- Trial name
- NCT03765502
- Testing
- Nasal Glucagon Device (NG), GEK, IM Glucagon
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A First-time-in-human Study of BGB149
This clinical trial is a Phase I, first-in-human. The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of BGB149 after single IV doses in healthy male and…
- Trial name
- NCT03795142
- Testing
- BGB149
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Bipolar Depression
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
The purpose of this first in human (FIH) study is to investigate the safety, tolerability, pharmacokinetics ( how the body handles the drug) and pharmacodynamics (how the drug affects the body) of PF-04455242-01 in healthy adult…
- Trial name
- NCT00938301
- Testing
- PF-04455242
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers
The objective of the present study was to obtain information about the safety, tolerability and pharmacokinetics of BIIR 561 CL after continuous intravenous administration of two increasing doses in healthy elderly volunteers…
- Trial name
- NCT02223507
- Testing
- BIIR 561 CL
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension Due to Left Heart Disease
A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)
Researchers are looking for a better way to treat people who have pulmonary hypertension (PH) due to left heart disease. PH due to left heart disease is a condition of high blood pressure in the vessels of the lungs caused by…
- Trial name
- NCT06048120
- Testing
- BAY2701250 IV, BAY2701250 SC
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bayer
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pain
Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704
The primary aim for this study is to investigate the safety and tolerability of the AZD1704, first time in man.
- Trial name
- NCT00692042
- Testing
- AZD1704
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers
Investigate the bioavailability of BI 1356 BS and of metformin after concomitant multiple oral administration of 10 mg BI 1356 BS tablets and 3 x 850 mg metformin in comparison to BI 1356 BS and metformin given alone
- Trial name
- NCT02183506
- Testing
- Metformin, BI 1356 BS
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function
The study will investigate whether administration of clazosentan can affect normal heart function in healthy subjects
- Trial name
- NCT03657446
- Testing
- Clazosentan, Moxifloxacin
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy Subjects
A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin
A study in healthy male subjects to investigate whether administration of ACT-541468 can affect the fate in the body (amount and time of presence in the blood) of rosuvastatin
- Trial name
- NCT03339752
- Testing
- Rosuvastatin, ACT-541468
- Where
- Czechia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy
Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers
The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIIR 561 after continuous intravenous administration of increasing doses in healthy young volunteers
- Trial name
- NCT02222961
- Testing
- BIIR 561 CL
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers
Safety, tolerability and pharmacokinetics of BIII 890
- Trial name
- NCT02269215
- Testing
- BIII 890 CL
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Tuberculosis
Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PNU-100480 (PF-02341272) after a single dose in healthy adult volunteers.
- Trial name
- NCT00871949
- Testing
- PNU-100480
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Sequella, Inc.
Gonococcal (GC) Infection
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914
The purpose of this study is to assess the safety and tolerability of orally administered AZD0914 in healthy adult subjects.
- Trial name
- NCT01929629
- Testing
- Part A, Part B
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function
Two-part Phase 1 study to assess the effect of single therapeutic and supra-therapeutic doses of lucerastat on the QT/QTc interval duration in healthy subjects (Part A: Pilot study; Part B: TQT study)
- Trial name
- NCT03832452
- Testing
- Lucerastat (Treatment A), Moxifloxacin, Lucerastat (Treatment B)
- Where
- Netherlands
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Drug Interactions
Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants
BAY1902607 is a new type of drug under clinical development for different conditions including the treatment of endometriosis, i.e. a condition where the tissue that usually grows inside the womb grows outside of the womb.
- Trial name
- NCT03789890
- Testing
- BAY1902607, Itraconazole
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Opioid Overdose
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
The purpose of this study is to determine the pharmacodynamics (change in minute ventilation) of nalmefene when given as an autoinjector intramuscularly (IM; into the thigh) compared to naloxone when given intranasally (IN; into…
- Trial name
- NCT06719986
- Testing
- Nalmefene HCl injection, Naloxone HCl intranasal
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP